Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · LCTX · as of Jun 8, 2026
Key Statistics
Explore Lineage Cell Therapeutics, Inc. Data
lctx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
Competitors & Peers
lctx competitorsLCTX
ADCT
AUTL
BNTC
FULC
GALTStock Performance
Full HistoryAbout Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company …
what is lineage cell therapeutics, inc. · lctx stock overview · lineage cell therapeutics, inc. company profile · who is lineage cell therapeutics, inc. ceo · lctx AMEX · lineage cell therapeutics, inc. headquarters · lineage cell therapeutics, inc. business segments
About Stock Overview & Key Data
Lineage Cell Therapeutics, Inc. (LCTX) is a Healthcare company in the Biotechnology industry, listed on AMEX since Mar 5, 1992. As of the latest trading session, LCTX stock price is $1.19, with a market capitalization of $296.7M. The stock has returned +65.55% over the past 12 months and -28.74% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Lineage Cell Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Lineage Cell Therapeutics, Inc. reported revenue of $14.6M and net income of -$63.5M. For detailed data — including Lineage Cell Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Lineage Cell Therapeutics, Inc. (LCTX) stock price is $1.19. The stock is traded on AMEX under the ticker symbol LCTX. The 52-week range is $0.65 – $2.09.